Stay updated on Copanlisib and Nivolumab in Lymphoma Clinical Trial

Sign up to get notified when there's something new on the Copanlisib and Nivolumab in Lymphoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Copanlisib and Nivolumab in Lymphoma Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    8 days ago
    Change Detected
    Summary
    The page now displays the ClinicalTrials.gov record for the copanlisib and nivolumab trial in recurrent or refractory large B-cell lymphoma. It includes the completed study status and detailed information about the protocol, outcomes, eligibility, and participating locations.
    Difference
    65%
    Check dated 2026-11-07T12:27:08.000Z thumbnail image
  3. Check
    14 days ago
    Change Detected
    Summary
    The footer revision number changes from v3.7.2 to v3.8.0 while the page continues to show a 403 Forbidden error instead of the study record.
    Difference
    0.2%
    Check dated 2026-10-31T13:07:52.000Z thumbnail image
  4. Check
    21 days ago
    Change Detected
    Summary
    A site-wide NIH notice says federal agencies are using “Super Intelligence” in place of “Artificial Intelligence” during a transition and links to updates and FAQs.
    Difference
    1%
    Check dated 2026-10-24T13:37:23.000Z thumbnail image
  5. Check
    28 days ago
    Change Detected
    Summary
    The footer revision identifier changes from v3.7.1 to v3.7.2. The page continues to display a 403 Forbidden error instead of the study record.
    Difference
    0.2%
    Check dated 2026-10-17T13:47:11.000Z thumbnail image
  6. Check
    35 days ago
    Change Detected
    Summary
    The footer’s ClinicalTrials.gov revision identifier changes from v3.7.0 to v3.7.1, while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-10T13:38:55.000Z thumbnail image
  7. Check
    56 days ago
    Change Detected
    Summary
    The page now shows a 403 Forbidden error, replacing the previous study details with an access-restricted message. The detailed trial content for the study has been removed or hidden.
    Difference
    20%
    Check dated 2026-09-19T19:24:32.000Z thumbnail image

Stay in the know with updates to Copanlisib and Nivolumab in Lymphoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Copanlisib and Nivolumab in Lymphoma Clinical Trial page.